Treatment options for Alzheimer’s disease (AD) are limited because of the inability of drugs to cross the blood–brain barrier (BBB). A promising strategy to overcome this obstacle is the use of nanoparticles (NPs). Previously, we showed that intraperitoneal administration of liposomes functionalized with phosphatidic acid and an ApoE-derived peptide (mApoE-PA-LIP) reduces brain beta-amyloid (Aβ) burden and ameliorates impaired memory in AD mice. Here, we investigated lung administration as an alternative, non-invasive NP delivery route for reaching the brain. Our results show that mApoE-PA-LIP were able to cross the pulmonary epithelium ([14C]-PA permeability = 6.5 ± 2.0 × 10–6 cm/min) in vitro and reach the brain (up to 0.6 μg PA/g brain) following in vivo intratracheal instillations. Lung administration of mApoE-PA-LIP to AD mice significantly decreased total brain Aβ (–60%; p < 0.05) compared to untreated mice. These results suggest that pulmonary administration could be exploited for brain delivery of NPs designed for AD therapy. [Figure not available: see fulltext.]

Sancini, G., DAL MAGRO, R., Ornaghi, F., Balducci, C., Forloni, G., Gobbi, M., et al. (2016). Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer’s disease murine model. NANO RESEARCH, 9(7), 2190-2201 [10.1007/s12274-016-1108-8].

Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer’s disease murine model

SANCINI, GIULIO ALFREDO
Primo
;
DAL MAGRO, ROBERTA
;
RE, FRANCESCA
2016

Abstract

Treatment options for Alzheimer’s disease (AD) are limited because of the inability of drugs to cross the blood–brain barrier (BBB). A promising strategy to overcome this obstacle is the use of nanoparticles (NPs). Previously, we showed that intraperitoneal administration of liposomes functionalized with phosphatidic acid and an ApoE-derived peptide (mApoE-PA-LIP) reduces brain beta-amyloid (Aβ) burden and ameliorates impaired memory in AD mice. Here, we investigated lung administration as an alternative, non-invasive NP delivery route for reaching the brain. Our results show that mApoE-PA-LIP were able to cross the pulmonary epithelium ([14C]-PA permeability = 6.5 ± 2.0 × 10–6 cm/min) in vitro and reach the brain (up to 0.6 μg PA/g brain) following in vivo intratracheal instillations. Lung administration of mApoE-PA-LIP to AD mice significantly decreased total brain Aβ (–60%; p < 0.05) compared to untreated mice. These results suggest that pulmonary administration could be exploited for brain delivery of NPs designed for AD therapy. [Figure not available: see fulltext.]
Articolo in rivista - Articolo scientifico
Alzheimer’s disease; ApoE-derived peptide; liposomes; lung administration; nanoparticles;
ApoE-derived peptide lung administration nanoparticles Alzheimer’s disease liposomes
English
2016
9
7
2190
2201
reserved
Sancini, G., DAL MAGRO, R., Ornaghi, F., Balducci, C., Forloni, G., Gobbi, M., et al. (2016). Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer’s disease murine model. NANO RESEARCH, 9(7), 2190-2201 [10.1007/s12274-016-1108-8].
File in questo prodotto:
File Dimensione Formato  
NanoResearch 2016.pdf

Solo gestori archivio

Descrizione: articolo principale
Dimensione 1.94 MB
Formato Adobe PDF
1.94 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/111552
Citazioni
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 15
Social impact